WuXi AppTec provides fully integrated pharmaceutical, biotechnology and medical device R&D services to improve the success of research and shorten the time of development by offering customers world-class capabilities and unparalleled capacities.
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical and medical device outsourcing company with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services across the discovery-to-commercialization spectrum.
Its Laboratory Services are full range of discovery and development services for pharmaceuticals; development and testing services for biotherapeutics and medical devices; and comprehensive toxicology services. Manufacturing services are for advanced intermediates and active pharmaceutical ingredients (APIs); cell banking services; and cGMP manufacturing for cellular therapeutics and combination/tissue-based products.
WuXi AppTec's primary China-based facilities include a 630,000-square-foot R&D center in Shanghai Waigaoqiao Free Trade Zone; a 220,000-square-foot process development/cGMP-quality manufacturing plant and a 350,000-square-foot expanded facility under construction in Jinshan area of Shanghai; and a 130,000-square-foot R&D center in Tianjin. A 323,450-square-foot toxicology center is under construction in Suzhou.
On August 9, 2007, the parent company WuXi PharmaTech (Cayman) Inc. became a New York Stock Exchange listed company and its American Depositary Shares trade under the symbol WX.
Since April 2008, the name of WuXi AppTec's China operations, WuXi PharmaTech Co Ltd, has been changed to WuXi AppTec Co Ltd; and the name of its U.S. operations, AppTec Laboratory Services, Inc., to WuXi AppTec, Inc.